论文部分内容阅读
目的:观察甘露聚糖肽联合阿片类药物治疗癌痛的临床效果。方法:采取随机、对照试验方法,64例晚期恶性肿瘤伴疼痛的患者,年龄37~69岁,VAS评分≥6,随机分为两组:吗啡组32例,甘露聚糖肽+吗啡组32例。达到疼痛缓解时(VAS评分≤3分)维持给药直至观察终点,然后比较治疗前后的疼痛缓解程度、吗啡日均消耗量、生活质量的改变。结果:与治疗前相比,两组癌痛均有不同程度的缓解,联合用药组总缓解率高于单药组(P<0.05);联合用药组的吗啡日均消耗量比单药组少(P<0.05);联合用药组患者生活质量较单药组明显提高。结论:甘露聚糖肽联合吗啡能有效地控制癌痛,减少吗啡的用量,并能提高患者生活质量。
Objective: To observe the clinical effect of mannan peptide and opioid in the treatment of cancer pain. Methods: A randomized, controlled trial of 64 patients with advanced malignancies with pain, aged 37-69 years and VAS score ≥ 6 were randomly divided into two groups: 32 in morphine group, 32 in mannan peptide plus morphine group . When pain relief (VAS score ≤3) was maintained until the end of observation, pain relief before and after treatment, daily consumption of morphine and quality of life were compared. Results: Compared with those before treatment, the cancer pain in both groups was relieved to some extent. The total remission rate in combination group was higher than that in single drug group (P <0.05). The daily consumption of morphine in combination group was less than that in single drug group (P <0.05). The quality of life in combination group was significantly higher than that in single drug group. Conclusion: Mannan peptide combined with morphine can effectively control cancer pain, reduce the dosage of morphine and improve the quality of life of patients.